Brazil Generic Drug Market Share, Size Trends and Forecast 2017-2022
Brazil generic drug market has grown at a CAGR of 15% during 2010-2016. Some of the factors which have facilitated the market growth include government initiatives, increase in aging-population and growth in the rate of lifestyle diseases. To get more infromation about the market, please visit @ http://www.imarcgroup.com/brazil-generic-drug-market Contact Us IMARC Group USA: +1-631-791-1145 Email: sales@imarcgroup.com Website: http://www.imarcgroup.com Follow us on twitter : @imarcglobal
Brazil generic drug market has grown at a CAGR of 15% during 2010-2016. Some of the factors which have facilitated the market growth include government initiatives, increase in aging-population and growth in the rate of lifestyle diseases.
To get more infromation about the market, please visit @ http://www.imarcgroup.com/brazil-generic-drug-market
Contact Us
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: http://www.imarcgroup.com
Follow us on twitter : @imarcglobal
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Brazil</strong> <strong>Generic</strong> <strong>Drug</strong> <strong>Market</strong>: Industry <strong>Trends</strong>, <strong>Share</strong>,<br />
<strong>Size</strong>, Growth, <strong>Forecast</strong> <strong>and</strong> Opportunity <strong>2017</strong>-<strong>2022</strong><br />
Copyright © IMARC. All Rights Reserved
About IMARC Group<br />
Report Description<br />
IMARC is a leading advisor on management strategy <strong>and</strong> market research worldwide. We partner with<br />
clients in all sectors <strong>and</strong> regions to identify their highest-value opportunities, address their most<br />
critical challenges, <strong>and</strong> transform their businesses.<br />
IMARC’s information products include major market, scientific, economic <strong>and</strong> technological<br />
developments for business leaders in pharmaceutical, industrial, <strong>and</strong> high technology organizations.<br />
<strong>Market</strong> forecasts <strong>and</strong> industry analysis for biotechnology, advanced materials, pharmaceuticals, food<br />
<strong>and</strong> beverage, travel <strong>and</strong> tourism, nanotechnology <strong>and</strong> novel processing methods are at the top of the<br />
company’s expertise.<br />
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies <strong>and</strong><br />
markets with close cooperation at all levels of the client organization. This ensures that our clients<br />
achieve unmatchable competitive advantage, build more proficient organizations, <strong>and</strong> secure lasting<br />
results.
Report Description <strong>and</strong> Highlights<br />
Report Description<br />
<strong>Brazil</strong> <strong>Generic</strong> <strong>Drug</strong> <strong>Market</strong> Driven by Government Initiatives <strong>and</strong> Public Health<br />
System<br />
<strong>Brazil</strong> generic drug market has grown at a CAGR of 15% during 2010-2016. Some of the factors<br />
which have facilitated the market growth include government initiatives, increase in agingpopulation<br />
<strong>and</strong> growth in the rate of lifestyle diseases.<br />
The latest report by IMARC Group titled, “<strong>Brazil</strong> <strong>Generic</strong> <strong>Drug</strong> <strong>Market</strong>: Industry <strong>Trends</strong>, <strong>Share</strong>,<br />
<strong>Size</strong>, Growth, <strong>Forecast</strong> <strong>and</strong> Opportunity <strong>2017</strong>-<strong>2022</strong>”, finds that the <strong>Brazil</strong> generic drug market<br />
reached a value of more than US$ 80 Billion in 2016, growing at a CAGR of around 15% during<br />
2010-2016. In 1999, a law was passed by the government of <strong>Brazil</strong> – The <strong>Generic</strong> <strong>Drug</strong>s Law –<br />
which allowed the substitution of generic drugs for trademark br<strong>and</strong>ed drugs. This law authorized<br />
laboratories to h<strong>and</strong>le <strong>and</strong> sell drugs, thereby enabling commercialisation <strong>and</strong> availability of<br />
previously more expensive br<strong>and</strong>ed drugs after the expiry of their patents. This has helped in<br />
improving the quality of drugs <strong>and</strong> facilitating the consumers to access quality drug treatment.<br />
Get Sample of the Report:<br />
http://www.imarcgroup.com/request?type=report&id=696&flag=B
Report Description <strong>and</strong> Highlights<br />
Report Description
Report Description <strong>and</strong> Highlights<br />
Report Description<br />
Highlights of <strong>Brazil</strong> generic drug market:<br />
• The <strong>Generic</strong> <strong>Drug</strong>s Law gave impetus to the market <strong>and</strong> helped in improving the quality of<br />
the generic drugs.<br />
• Free distribution of medicines for the treatment of various diseases by the government<br />
<strong>and</strong> public health system provide stimulus for the market growth.<br />
• The factors such as increasing aging-population <strong>and</strong> growing lifestyle diseases have<br />
further driven the dem<strong>and</strong> for generic drugs in the region.<br />
The <strong>Brazil</strong>ian generic drug market has been spurred by the active participation of the government<br />
<strong>and</strong> health-care organizations. Besides passing the <strong>Generic</strong> <strong>Drug</strong>s Law, the government has also<br />
made constant efforts in promoting the sales of generic drugs. Most importantly, The <strong>Brazil</strong>ian<br />
Federal Government represents the biggest pharmaceutical client itself. It distributes free<br />
contraceptives <strong>and</strong> medicines for hypertension, asthma, diabetes, Parkinson's, glaucoma,<br />
osteoporosis <strong>and</strong> rhinitis through their programmes <strong>and</strong> initiatives. Moreover, the <strong>Brazil</strong>ian public<br />
health system; the Sistema Único de Saúde, avails generic versions of the medicines for the<br />
treatment of various diseases such as AIDS, tuberculosis, Alzheimer, Hepatitis, transplants, Lupus,<br />
etc.
Report Description <strong>and</strong> Highlights<br />
Report Description<br />
Some of the other factors which have contributed in influencing the market include an increase in<br />
the aging-population <strong>and</strong> the growing prevalence of lifestyle diseases. Considering the<br />
developments, the market is further expected to reach a value of almost US$ 190 Billion by <strong>2022</strong>.<br />
The report examines the competitive l<strong>and</strong>scape of the market <strong>and</strong> provides the details of the<br />
major players of the market such as EMS S.A., Sanofi Group, Eurofarma Laboratórios S.A.,<br />
Hypermarcas S.A., S<strong>and</strong>oz, Ache Laboratories <strong>and</strong> União Química Farmacêutica Nacional S.A. The<br />
report also provides an in-depth analysis on the historical, current <strong>and</strong> future trends in the generic<br />
drug market in <strong>Brazil</strong>. This research report serves as an exceptional tool to underst<strong>and</strong> the drivers,<br />
sales trends, volume trends, market structure, competitive l<strong>and</strong>scape, regulations, key players,<br />
manufacturing <strong>and</strong> the outlook of generic drugs in <strong>Brazil</strong>. This report can serve as an excellent<br />
guide for investors, researchers, consultants, marketing strategists <strong>and</strong> all those who want to gain<br />
an insight into the market for generic drugs in <strong>Brazil</strong>.<br />
Browse full report with TOC @ http://www.imarcgroup.com/brazil-generic-drug-market<br />
Find more research reports related to Healthcare Industry @<br />
http://www.imarcgroup.com/categories/healthcare-market-research-reports
Report Description <strong>and</strong> Highlights<br />
Report Description<br />
© <strong>2017</strong> IMARC All Rights Reserved<br />
This Publication <strong>and</strong> all it’s contents unless otherwise mentioned are copyrighted in the name of<br />
International <strong>Market</strong> Analysis Research <strong>and</strong> Consulting (IMARC). No part of this publication may be<br />
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be<br />
used in any form or by <strong>and</strong> means graphic electronic or mechanical, including photocopying, recording,<br />
taping or by information storage or retrieval, or by any other form, without the express consent of<br />
International <strong>Market</strong> Analysis Research <strong>and</strong> Consulting (IMARC).<br />
Disclaimer: All contents <strong>and</strong> data of this publication, including forecasts, data analysis <strong>and</strong> opinion have been<br />
based on information <strong>and</strong> sources believed to be accurate <strong>and</strong> reliable at the time of publishing.<br />
International <strong>Market</strong> Analysis Research <strong>and</strong> Consulting makes no representation of warranty of any kind as to<br />
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any<br />
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.<br />
IMARC, IMARC Group <strong>and</strong> Global Therapy Insight Series are registered trademarks of International <strong>Market</strong><br />
Analysis Research <strong>and</strong> Consulting. All other trademarks used in this publication are registered trademarks of<br />
their respective companies.
Contact Us<br />
FOR MORE DETAILS<br />
Visit us at :<br />
http://www.imarcgroup.com<br />
Stay With Us:<br />
TELEPHONE: +1-631-791-1145<br />
E-MAIL: sales@imarcgroup.com